HALOZYME THERAPEUTICS, INC. Unrecognized Tax Benefits that Would Impact Effective Tax Rate
HALOZYME THERAPEUTICS, INC. (HALO) had Unrecognized Tax Benefits that Would Impact Effective Tax Rate of $25.70 million as of 2025-12-31, per its 10-K filed 2026-02-17.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate · last filed 2026-02-17
- 2025-12-31: Unrecognized Tax Benefits that Would Impact Effective Tax Rate $25.70M.
- 2024-12-31: Unrecognized Tax Benefits that Would Impact Effective Tax Rate $23.60M.
- 2020-12-31: Unrecognized Tax Benefits that Would Impact Effective Tax Rate $300.00K.
- 2019-12-31: Unrecognized Tax Benefits that Would Impact Effective Tax Rate $200.00K.
| Period end | Unrecognized Tax Benefits that Would Impact Effective Tax Rate |
|---|---|
| 2025-12-31 | $25.70M 10-K · filed 2026-02-17 |
| 2024-12-31 | $23.60M 10-K · filed 2025-02-18 |
| 2020-12-31 | $300.00K 10-K · filed 2021-02-23 |
| 2019-12-31 | $200.00K 10-K · filed 2020-02-24 |
| 2018-12-31 | $200.00K 10-K · filed 2019-02-21 |
| 2017-12-31 | $0.00 10-K · filed 2018-02-20 |
| 2016-12-31 | $200.00K 10-K · filed 2017-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |